Tokyo – April 16, 2026 – LPIXEL Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Tomihisa Kamada; hereafter “LPIXEL”) is pleased to announce that its medical imaging diagnostic support AI “EIRL” series has obtained regulatory approval in six ASEAN countries (Vietnam, the Philippines, Thailand, Indonesia, Malaysia, and Singapore). Preparations for commercialization and marketing are currently underway in each territory.

Regulatory approval allows LPIXEL to offer the EIRL series to medical institutions across these countries. EIRL supports diagnosis by detecting suspected lung field abnormalities, including lung nodules, and classifying the probability of tuberculosis from chest X-ray images. Trials are already underway at several local institutions, and LPIXEL will promote sales through close collaboration with local partners and PACS (Picture Archiving and Communication Systems) providers in each market. LPIXEL aims to enhance the quality of regional healthcare by accelerating the adoption of medical AI not only in Japan, but also across Asia.

[Regulatory Approvals/Certifications in Each Territory]

• Vietnam (December 2024)
  • EIRL Viewer: 240003132 / PCBB‑HCM
  • EIRL Chest Metry: 240003133 / PCBB‑HCM
  • EIRL Chest XR: 240003134 / PCBB‑HCM
• Philippines (January 2025)
  • EIRL Viewer: CDRRHR‑CMDN‑2023‑1279022
  • EIRL Chest Metry: CDRRHR‑CMDN‑2024‑1097983
  • EIRL Chest XR: CDRRHR‑CMDN‑2025‑1117476
• Thailand
  • EIRL Chest Screening: 68‑2‑2‑2‑0000605 (January 2025)
  • EIRL Chest TB: 68‑2‑2‑2‑0009328 (September 2025)
• Indonesia (May 2025)
  • EIRL Viewer: KEMENKES RI AKL 21501520304
  • EIRL Chest Metry: KEMENKES RI AKL 21501520298
  • EIRL Chest XR: KEMENKES RI AKL 21501520303
• Malaysia (November 2025)
  • EIRL Chest Screening*: GB3725525‑215404

• Singapore (March 2026)
  • EIRL Chest Screening*: MDPR260324D0005

* The exact product configuration in each territory varies according to local medical device regulations:
・Malaysia: EIRL Chest XR, EIRL Chest Metry, EIRL VIewer 
・Singapore: EIRL Chest XR, EIRL Chest Metry

For details on each product, please refer to the product website: https://eirl.ai/

Background

In Southeast Asia, the disease landscape has evolved due to advances in infectious disease control and changes in lifestyle. Currently, non-communicable diseases (NCDs) such as cardiovascular disease and cancer account for a large portion of total mortality, making them major health challenges(*1). Risk factors such as the impact of air pollution and high smoking rates remain high in this region, and are recognized as contributing to the increase in these diseases(*2).

On the other hand, tuberculosis remains a significant public health challenge, with more than one-third of the world’s new cases concentrated in the Southeast Asia region(*3).

Despite this, countries in the region face structural hurdles, including a shortage of physicians and medical resources compared to developed nations. In many locations, specialist-led diagnostic infrastructure  is not adequately established, particularly in rural areas and smaller medical facilities. LPIXEL believes that the adoption of AI-based diagnostic support can help to standardize the quality of care and enhance patient safety. To advance the early detection and prevention of tuberculosis, LPIXEL has been promoting the use of AI diagnostic support, including piloting AI-enhanced mobile tuberculosis screening (utilizing buses equipped with X-ray imaging devices) in collaboration with the Faculty of Public Health at Mahidol University in Thailand since March 2025.

Press Release on January 27, 2025: “Launch of AI-powered Mobile TB Screening in Thailand” (https://lpixel.net/news/press-release/2025/11416/)

For more information on the medical situation in Southeast Asia, please also refer to LPIXEL note (in Japanese): “Significance and Challenges of Medical AI Dissemination in Southeast Asia – Signs Seen from Overseas Expansion – | LPixel Inc.“

(*1)WHO South-East Asia Region: Tuberculosis overview（URL：https://www.who.int/southeastasia/health-topics/tuberculosis）
(*2)WHO South-East Asia Region  –  Tobacco Control in South-East Asia Region（URL：https://www.who.int/southeastasia/health-topics/tobacco/tobacco-control-in-the-south-east-asia-region
(*3)WHO South-East Asia Region: Tuberculosis overview（URL：https://www.who.int/southeastasia/health-topics/tuberculosis）

Future Outlook

LPIXEL aims to create an environment where AI-powered diagnostic support becomes a standard of care by providing the EIRL series to medical institutions throughout Southeast Asia. While trials are already underway at multiple medical institutions, we plan to scale implementation to major medical centers in each country. Furthermore, we will work closely with local sales partners and PACS providers to offer operational support tailored to regional medical infrastructure and clinical workflows. By continuing to refine our products and introduce new features in line with evolving national regulations and healthcare systems, LPIXEL remains committed to the improvement of regional medical care.

Product Inquiries

LPIXEL Inc., Global Business Development Office
TEL: +81-3-6259-1713
Mail: ml-global@lpixel.net

About EIRL – Medical Imaging Diagnostic Support AI Technology

LPIXEL’s flagship series of AI image analysis software, ‘EIRL’, supports clinicians in interpreting a range of medical images—from radiological scans (X-ray, CT, MRI) to colonoscopy—with greater accuracy and efficiency.

Installed at over 1200 medical institutions in Japan with over 16 million clinical analyses performed (cumulative, as of February 2026), EIRL is enhancing diagnostic confidence and alleviating clinician burden by helping to prevent critical findings from being missed. 

For more information, please visit the EIRL website for healthcare professionals: https://eirl.ai/

About LPIXEL Inc.

Established in 2014, LPIXEL is a leading provider of artificial intelligence-based image analysis technologies within the medical and life science industries.

Dedicated to improving the lives of clinicians and the health of patients, LPIXEL’s flagship series of Software as a Medical Device (SaMD) products, ‘EIRL’, assists clinicians with the interpretation of medical images including radiological scans (X-ray, CT, MRI) and colonoscopy, and has performed over 16 million analyses to date (as of February 2026).

In addition to clinical products, LPIXEL also accelerates R&D across the life sciences by delivering bespoke image analysis solutions to leading pharmaceutical and medical device companies with a focus on addressing challenges across all stages of the drug development pipeline, from drug discovery to manufacturing.

For more information, please visit https://lpixel.net/en/